MAP2K7 and melanoma: Importantly, inactivation of this pathway delays resistance and significantly improves survival following combined BRAF and MEK inhibition in multiple in vivo melanoma models, suggesting this pathway may provide therapeutic opportunities to disrupt non-genetic mechanisms of resistance and delay disease relapse in melanoma.